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ABSTRACT 
Asthma and mood disorders such as anxiety or depression are associated with adverse 
pregnancy, delivery, and perinatal outcomes. There is an association between mood disorders 
and asthma and there may be common mechanisms on how the conditions affect pregnancy 
outcomes. For example, some of the associations may be explained by genetic or 
environmental factors, familial confounding. In this thesis we have investigated how asthma 
and anxiety or depression complicates pregnancy and delivery outcomes in a combination of 
large population-based registers and smaller clinical cohorts, using family design methods to 
adjust for possible shared genetic and environmental factors. 
In Study I and II we studied the associations between maternal asthma and adverse 
pregnancy outcomes, such as preeclampsia, placental abruption, mode of delivery, birth 
weight, and gestational age, using Swedish population-based cohorts. For Study II we 
identified cousins and siblings who were pregnant and gave birth during the same study 
period. We found that maternal asthma was associated with many of the adverse outcomes, 
such as preeclampsia (Study I, II), and that the associations were not confounded by factors 
shared within families (Study II). There were also increased risks for some adverse outcomes 
based on asthma severity and control (Study I).  
For Study III we investigated the impact of maternal asthma on early foetal growth, assessed 
by routine ultrasound scan in second trimester. The study population originated from the 
MAESTRO study of 1693 women prospectively followed during pregnancy. We did not find 
any significant effect of maternal asthma on early foetal growth. There was also no difference 
between women with and without asthma for birth weight and gestational age 
In Study IV, we estimated the association between maternal anxiety or depression and 
pregnancy outcomes using a population-based cohort. We found that maternal anxiety or 
depression was associated with several adverse pregnancy outcomes and that the associations 
were not confounded by familial factors shared by cousins and siblings. There was no 
interaction between asthma and anxiety or depression for any of the outcomes except for 
elective caesarean section. There were also higher odds for elective caesarean section in 
women with anxiety or depression diagnosis without medication compared to those with 
medication. 
In conclusion, maternal asthma as well as maternal anxiety or depression were associated 
with several serious pregnancy complications and adverse perinatal outcomes. Familial 
confounding did not explain the observed associations. Apart from elective caesarean section, 
we did not see any interaction between maternal asthma and anxiety or depression on the 
studied adverse pregnancy outcomes. This means that targeting the asthma disease as well as 
anxiety/depression in the pregnant woman will continue to be important in reducing risks for 
adverse outcomes in pregnancy. Greater awareness and proper management would most 
likely improve outcomes.  
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1 INTRODUCTION 
A pregnancy can be demanding on the pregnant woman and, although in many cases 
uneventful, sometimes associated with several adverse outcomes such as preeclampsia, 
instrumental delivery, premature birth, and low birth weight of the child. 
Having a chronic disease while pregnant is also associated with adverse outcomes and 
although continued medication is generally recommended, many pregnant women are under-
medicated. Among the most common chronic diseases in all age-groups is asthma, which has 
the potential to complicate the course of pregnancy. Asthma is also associated with anxiety 
and depression, which in turn may also affect pregnancy. 
The overall aim for the thesis is to study the association between asthma, anxiety or 
depression and pregnancy, delivery, and perinatal outcomes, using advanced family design in 
population-based national registers and a clinical cohort. 
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2 BACKGROUND 
2.1 ASTHMA 
2.1.1 Asthma prevalence and characteristics 
Asthma is one of the most common chronic diseases affecting more than 300 million people 
worldwide1 with a prevalence in some countries of up to 20%.2 In Sweden, the prevalence is 
estimated to 8-10% in adults.3, 4 It can present itself in various ways but is commonly 
characterised by chronic inflammation and obstructive airways. Usually, to diagnose asthma, 
a history of respiratory symptoms is needed. Symptoms include wheezing, chest tightness, 
cough, and shortness of breath in combination with reduced expiratory air flow. Even without 
treatment, asthma can produce mild symptoms and vary over time, especially if associated 
with allergic respiratory disease such as pollen allergy, or in some cases respiratory tract 
infections such as the common cold.5 There are also episodes of more severe symptoms with 
even life-threatening complications (exacerbations) which pose significant burden on the 
bearers of disease as well as health care systems.6  
There is diversity in asthma and there are several different phenotypes described which 
include both allergic- and non-allergic asthma as well as late-onset asthma.7 There is, 
however, poor correlation between the specifics of different phenotypes and treatment 
responses.8 
2.1.2 Asthma diagnosis and treatment 
According to Global Initiative for Asthma (GINA) guidelines5, asthma diagnose is based on 
criteria such as a history of more than one of the symptoms wheeze, shortness of breath, 
cough, and chest tightness which vary over time and often are triggered by a stimulant (such 
as cold air, exercise).  
To obtain an adequate asthma control, it is necessary to continuously evaluate symptoms. For 
this purpose, in adults as well as in adolescents and children, some asthma control tools are 
available and widely used, such as the Asthma Control Test (ACT), in which a score is set 
based on different levels of symptoms.9, 10 However, only evaluating current symptoms might 
lead to inadequate treatment since respiratory symptoms can be due to other conditions than 
asthma (obesity, lack of fitness etc.) and some patients also have few symptoms despite a low 
lung function.  
Spirometry is an essential instrument in evaluating asthma status and control. It should be 
done in a standardised way with highly trained staff. If a reversibility test is to be done, which 
is often the case to discern chronic obstructive disease from reversible disease (asthma), the 
participant (patient) needs to be on medication hiatus at least for 4 hours before the 
examination if the participant is using short acting β2-agonists. Long acting β2-agonists 
should be avoided for at least 12 hours and smoking at least one hour prior to testing. Results 
are associated with patient’s age, gender, height, and weight and to properly interpret the 
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findings these variables need to be taken into consideration. The participant is first asked to 
do a forced expiratory manoeuvre, which will be repeated to get information on the FEV1 
(forced expiratory volume in one second). To test for reversibility, the participant is then 
asked to inhale a short acting bronchodilator – for instance salbutamol or terbutaline, and then 
do the test all over again.11, 12 If obstructive airways are present, the participant should 
perform better after medication, resulting in an improved FEV1,
13 Figure 1. 
 
 
Figure 1. Results of spirometry showing a normal (triangle-shaped) curve, a restrictive 
curve, and an obstructive curve. The forced vital capacity (FVC) is the amount of air (in 
litres) forcibly expired after maximum inhalation. Forced expiratory volume in one second 
(FEV1) is the volume (litres) forcibly expired in the first second after maximum inhalation. 
 
 
Just as lung function tests can add to the clinical picture14, exhaled nitric oxide (NO), a 
marker of airway inflammation, can together with data on FEV1 and FEV1/FVC predict risk 
of exacerbations.15-17 
Asthma treatment is handled in a step-wise approach.5 In step 1, a short-acting symptom 
reliever is used, often a short-acting β2-agonist (SABA). If this is not enough, medication 
with an inhaled corticosteroid (ICS) taken regularly is initiated, sometimes with addition of 
leukotriene receptor antagonists or low dose theophylline (step 2). A short-term PEF (Peak 
Expiratory Flow) monitoring can be used to evaluate the response to treatment. 
  5 
If the asthma is moderate to severe (step 3-4) addition of long acting β2-agonists (LABA) and 
increasing doses of ICS is needed. A more severe asthma that does not respond to inhalation 
treatment (step 5) may require add-on treatment such as anti-IgE and oral corticosteroids 
(Figure 2). 
 
 
Figure 2. Step-wise approach of asthma treatment.5 
 
2.1.3 Asthma and pregnancy 
Asthma is one of the most common chronic diseases during pregnancy.18, 19 Asthma 
symptoms may increase during pregnancy, which can be attributable either to worsening of 
asthma due to the pregnancy itself or inadequate medication.20, 21  
Mild and moderate well-controlled asthma is generally associated with an uncomplicated 
course of both pregnancy and delivery, but maternal asthma has also been associated with an 
increased risk for pregnancy complications, adverse labour characteristics, and perinatal 
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outcomes22-32 and poor asthma control seems to increase the risk of preeclampsia, preterm 
delivery and small for gestational age.33, 34 Moreover, exacerbations of asthma during 
pregnancy, often triggered by non-adherence to inhaled corticosteroid medication, are 
associated with risk of a low birth weight in offspring.35 
Although there are several studies on the association between asthma in pregnant women and 
pregnancy outcomes,22, 23, 25, 30, 36, 37 the previous studies are non-consistent.19, 24, 27, 38-40 It has 
been suggested that this discrepancy might be caused by variation in study size and that 
participation in smaller prospective studies is associated with better disease control and 
therefore better outcomes.40 Thus, there is a call for larger studies to assess the effect of 
maternal asthma, severity and control on pregnancy complications, labour, and perinatal 
outcomes. Larger studies may also allow adjustment for confounding factors that may affect 
exposure and outcomes, such as socioeconomic status, maternal weight and shared genetics 
and common environment. 
2.2 ANXIETY AND DEPRESSION 
2.2.1 Prevalence and characteristics of anxiety and depression 
Mood disorders such as anxiety and depression are common in all populations and it is 
estimated that about 20-30% will be affected some time during their lifetime.41, 42 Anxiety 
and depression are closely associated conditions, overlapping to a high extent for instance in 
terms of medication. They may affect not only psychological well-being but also other 
diseases such as asthma.43, 44 
Stress is considered a possible inductor of anxiety and depressive-like symptoms45 and 
anxiety and depression are often referred to as psychological distress where stress perhaps is 
situated in one end of a spectrum.46-50 Stress to some extent is very common and probably not 
dangerous, but too much stress might cause clinical symptoms like anxiety or depression, and 
ultimately lead to physical conditions such as adverse outcomes in pregnancy and maybe 
later morbidity in the child.51 Major stress events such as bereavement52 can be measured in 
registers but other types of stress are more difficult to assess. Using validated questionnaires53 
is a common approach, however they require clinical cohorts which are smaller and have 
lower power. 
2.2.2 Diagnosis and treatment of anxiety and depression 
Anxiety and depression are diagnosed by means of specific criteria, and widely used 
instruments are the DSM (Diagnostic and Statistical Manual of Mental Disorders)54, and ICD 
(International Classification of Disease).55 The instruments have differences, but the overall 
concordance is often good.56 Different scales are used as a complement and evaluation of 
treatment of mood disorders, such as Centre for Epidemiologic Studies Depression (CES-
D),57 the Positive and Negative Affect Schedule (PANAS)58 and the Perceived Stress Scale 
(PSS).59 
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Antidepressant medication is very common and, in the USA, used by on average 15% of 
women in reproductive age.60 During pregnancy the figures are lower and a recent Nordic 
study by Zoega et al. showed an exposure to antidepressant drugs during pregnancy of about 
4%.61 The basis of pharmacological treatment is a selective serotonin reuptake inhibitor 
(SSRI) – although the use of serotonin-norepinephrine reuptake inhibitors (SNRI) have 
increasingly become an alternative,62 often in combination with a mild sedative for 
improvement of sleep and anxiety relief.63 
2.2.3 Anxiety, depression, and pregnancy 
During pregnancy, anxiety and depressive symptoms are at least as common as in non-
pregnant women with a prevalence of 6-15%.64-66 Similar to asthma being a risk factor for 
adverse pregnancy and delivery outcomes, women reporting anxiety and depression during 
pregnancy have been displaying increased odds ratios for several of the same adverse 
outcomes.67-72 The mechanisms for the associations between anxiety or depression and 
adverse pregnancy outcomes are yet to be elucidated and factors shared within families (such 
as common genes and common environment) may play a role.73 
An association between anxiety, depression and asthma has been shown previously74 and 
may have common mechanisms for adverse pregnancy outcomes.67-69 Why this similarity 
exists and the mechanism behind it is however not fully clarified, and socioeconomic factors 
may have a large impact as well as common immune processes.74, 75 There may be interaction 
between maternal asthma and maternal anxiety or depression that leads to increased risks of 
adverse outcomes above what would be expected from the risk of each condition combined. 
2.3 PREGNANCY AND ADVERSE OUTCOMES 
2.3.1 Pregnancy Characteristics 
Pregnancy is a state of induced immuno-suppression76 which leads to inhibition of immune 
responses. This is a necessary process because of the foreign antigens presented by the 
foetus.77 During pregnancy, with the enlarging uterus, the diaphragm is elevated up to 4 cm 
which leads to a reduced functional residual capacity (the amount of air left after passive 
expiration). In a normal pregnancy, there are no significant alterations in forced vital 
capacity, peak expiratory flow rate or forced expiratory volume in 1 second.78 
2.3.2 Pregnancy Complications 
Although most pregnancies are uneventful in terms of complications there are adverse 
outcomes in pregnancy and delivery that can affect the woman, foetus, or both. 
Preeclampsia during pregnancy affects 3-7% of all pregnant women and is a potentially life-
threatening complication characterized by hypertension, elevated liver enzymes, proteinuria, 
headaches, and intrauterine growth restriction. The disease may be manifested after 
gestational week 20 and there is no real treatment except delivery.79 There are several 
hypotheses as to the pathogenesis of the disease. One of the most commonly accepted is a 
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two-step model with, firstly, a defect in the placental formation,80 perhaps due to an 
immunological maladaptation. The weakened utero-placental blood flow causes an impaired 
oxygen transport resulting in free radicals, an oxidative stress and eventually permanent 
tissue damage. In a second step, leakage of particles from the foetus due to the tissue damage 
leads to general endothelial damage and a systemic inflammation.81 
Gestational diabetes is a condition that affects 6% of all pregnancies and is associated with 
other pregnancy complications such as preeclampsia, caesarean section, foetal macrosomia, 
shoulder dystocia, and neonatal hypoglycaemia.82 
Premature contractions and premature rupture of membranes are associated with 
premature delivery which is a major contributor to perinatal morbidity and mortality.83 
A rare, but serious condition is placental abruption in which the placenta in part or in whole 
detaches prior to delivery. It is associated with severe morbidity and mortality in both mother 
and foetus/child84 and previous studies have shown an association between maternal asthma 
during pregnancy and placental abruption.85 
Labour dystocia is a risk factor for interventions during labour and is the most common 
indication for primary caesarean sections. Factors that contribute to prolonged labour and 
labour dystocia include advanced maternal age, obesity and labour induction.86 
The mode of delivery is associated with outcomes for mother and child – both in long term 
and short perspective. Although sometimes life-saving, caesarean section is also associated 
with both foetal and maternal morbidity.87 
Haemorrhage after delivery is the leading cause of maternal mortality worldwide. It is 
usually caused by uterine atony, lacerations, retained placenta, placenta accreta, coagulation 
defects, or uterine inversion but can also be caused by infections and genetic coagulation 
defects, such as von Willebrand’s disease.88 
Foetal growth can be affected by many conditions including and maternal asthma.89, 90 It is 
unclear if this occurs early in pregnancy or later. Foetal age is routinely determined by a 
second trimester ultrasound scan, in gestational week 18-20, but can be measured earlier. In 
the first trimester, gestational age by ultrasound scan is calculated by measurement of the 
crown-rump-length (CRL) and bi-parietal diameter (BPD).91, 92 Second trimester ultrasound 
scan estimates the gestational age by measuring the femur length (FL) and the BPD,93-95 and 
later during pregnancy repeated scans can assess intrauterine foetal growth.96 
The Apgar score was developed in 1952 by Dr. Virginia Apgar as a method for assessing the 
neonate’s immediate response to resuscitation at 1, 5, and 10 minutes after birth. The score is 
widely used but should not be interpreted as evidence of asphyxia in the child.97 
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2.4 EPIDEMIOLOGICAL INVESTIGATION OF OBSERVED ASSOCIATIONS 
2.4.1 Epidemiological methods 
To study the association between asthma and stress/anxiety/depression on the one hand and 
pregnancy, delivery, and perinatal outcomes on the other, one must rely on epidemiological 
approaches, of which some are described below. 
2.4.1.1 Randomised Controlled Trial 
The gold standard of evaluating a certain treatment or intervention is a randomised controlled 
trial (RCT) where a population is divided into randomly selected groups. One group receives 
an intervention whereas the other group receives no intervention in such a manner that neither 
participants nor testers are aware of what group they are in. A perfectly executed RCT can 
both show associations and state if there is causality, e.g. a given medication treats a certain 
disease. 
 RCT:s, however are difficult, costly and in many cases not possible to conduct. Also, if there 
is no intervention to be studied other approaches are needed. 
2.4.1.2 Observational cohort study 
A cohort study is an analytical observational study where one or several outcomes are 
measured in a group of individuals that are either exposed or unexposed to a certain variable 
and followed up after a specified time. The cohort can be patients selected based on medical 
records, a clinical cohort of prospectively collected data, register based data or a combination 
thereof. In Sweden, the universal use of the personal identity number, which is a unique 
identifier for each resident, enables linkage between different data sources.98 There are 
several Swedish national registers held by the National Board of Health and Welfare that can 
be used when studying disease. 
When doing an epidemiological study of pregnant women, the usage of the Medical Birth 
Register (MBR) is a very efficient path to take if one wants to create a large cohort. Linkage 
with other registers enables addition of data such as prescribed drugs, diagnoses and 
socioeconomy. A large dataset with many observations and many co-factors also allows for 
adjustment in calculations for potential confounders that might otherwise lead to a 
confounded, weaker or stronger association. 
2.4.1.3 Family design 
All confounders are however not known, or even measurable. For instance, there can be 
familial factors (genetic or common environment) that are closely associated to both exposure 
and outcome. With large enough number of observations, some of those unmeasured familial 
factors can be adjusted for by using a family-design approach.99, 100 In terms of family design, 
sibling comparison is one of the strongest. It can rule out alternative mechanisms that 
confound associations between early risk factors and later disease, including all unmeasured 
genetic and early life environmental factors shared by siblings. If an association remains after 
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having compared cases to unexposed siblings and cousins there is an indication that the 
exposure studied is a potential risk factor for the outcome. If however, an observed risk for 
adverse outcomes diminishes when using sibling and cousin controls, familial factor may be 
considered to have confounded an association observed in comparison to unrelated 
controls.101, 102 By using a family-based design, one does not confirm causality, but the 
method provides stronger support for a causal effect compared to ordinary observational 
studies.103 
2.4.1.4 Clinical cohort 
Creating a clinical cohort by prospectively collecting data is more time-consuming and less 
efficient than a register linkage, although a clinical cohort has some important advantages 
over register data. For instance, all information of interest may not be available in the 
registers, such as bio samples and lung function measurements. Moreover, the data in the 
registers can be less detailed than wanted, for example asthma diagnosis is available from the 
registers but not results from lung function test. 
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3 KNOWLEDGE GAPS AND AIMS 
More knowledge about the effects of asthma and asthma severity and -control is needed to 
identify measures to optimise care of pregnant women with asthma. This can be achieved 
with a combination of a register-based linkage study and a clinical cohort (aims 1, 2 and 3). 
It is not clear if the association between maternal asthma and adverse pregnancy outcomes is 
causal or confounded by genetic effects or/and environmental factors. More knowledge on 
the effects of genes and environment on asthma during pregnancy is needed (aim 2). 
Although studies on maternal asthma and pregnancy outcomes can be conducted using 
register data, more detailed and reliable data on those exposures (asthma prevalence, severity, 
and control) and outcomes (foetal growth in utero and pregnancy outcomes) can be collected 
using a clinical cohort. Also, few studies have assessed the effect of maternal asthma on 
ultrasound measured foetal growth90 (aim 3). 
Like asthma being a risk factor for adverse pregnancy and delivery outcomes, women 
reporting anxiety and depression during pregnancy have been displaying increased odds 
ratios for several of the same adverse outcomes.67-69 It is not clear whether this higher 
prevalence of adverse pregnancy outcomes after anxiety or depression remains after adjusting 
for genetic and shared environmental factors as can be done using sibling and cousin 
analyses. It is also not clear if there is an interaction between maternal asthma and 
anxiety/depression that affects adverse outcomes more than to be expected from each 
condition combined (aim 4). 
The specific aims are: 
Study I. To assess possible associations between maternal asthma, pregnancy, labour, 
and adverse birth characteristics as well as the effects of asthma severity and 
control on pregnancy complications and perinatal outcomes. 
Study II. To examine, in a family design approach, whether the associations between 
maternal asthma and adverse pregnancy, labour and perinatal outcomes are 
confounded by familial factors (genes and/or environment). 
Study III. To examine, in a clinical study, how maternal asthma and asthma control 
affects early foetal growth and pregnancy outcomes, taking maternal 
background factors and confounders into account. 
Study IV. To explore whether anxiety or depression during pregnancy is a risk factor 
for adverse pregnancy outcomes, adjusting for familial confounding in a 
sibling-cousin design, and whether there is an interaction between maternal 
asthma and anxiety or depression. 
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4 METHODOLOGICAL CONSIDERATIONS 
4.1 DATA SOURCES 
4.1.1 Register Data 
In Study I, II and IV, data were retrieved from the three registers held by The National Board 
of Health and Welfare (Socialstyrelsen), a government agency in Sweden under the Ministry 
of Health and Social Affairs, and two registers held by Statistics Sweden, a government 
agency responsible for official statistics and for other government statistics. 
We used health registers from the National Board of Health and Welfare. The Swedish 
Medical Birth Register (MBR) is a national register that, since 1973, includes 
approximately 99% of all pregnancies that result in delivery. The register comprises of six 
main parts: 1) patient ID (mother and child), 2) social background factors, 3) mother’s 
medical history, 4) pregnancy data, 5) delivery data and 6) perinatal data on the new born 
child.104, 105 All data in the register are prospectively collected: background factors at the first 
antenatal visit; data on medication use, mother’s weight, tobacco use updated throughout the 
pregnancy; and data on pregnancy- and delivery outcomes as well as perinatal data such as 
foetal weight, length, and asphyxia or hypoxia, at delivery. 
The National Patient Register (NPR), started in 1987, contains all diagnoses and 
procedures of in-patient care and, since 2001, also includes specialist out-patient care, 
covered to 75%.106 
One of the newer national registers is the Swedish Prescribed Drugs Register (SPDR), 
which started on 1 July 2005. It contains individually based data on dispensed prescribed 
drugs (ATC-codes), dosage, size of package and amount, date of prescription.107 
From Statistics Sweden we have used the Longitudinal Integration Database of Health 
Insurance and Labour Market Studies (LISA by Swedish acronym) to study 
socioeconomic status such as education level and yearly income,108 and the Multi 
Generation Registry (MGR) which contains information on all persons who have been 
registered in Sweden at some point since 1961 and born 1932 or later. The register contains 
connections between index persons and biological and adoptive parents.109, 110 
The Medical Birth Register allowed us to identify all women that gave birth during the study 
periods, which for Study I consisted of all Swedish women being pregnant and giving birth 
between 1 July 2006 and 31 December 2009 (N=284,214); for Study II and IV between 1 
January 2001 and 31 December 2013 (N=1,075,153). 
In Study II and IV we also identified the women’s full sisters and first cousins who gave birth 
during the same study period using the Multi Generation Register. 
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4.1.2 Clinical Data 
The MAESTRO cohort (Maternal Asthma Events, Stress and Offspring) was initiated in 
2011. The main research questions were about the effects of maternal asthma and maternal 
stress on pregnancy and pregnancy outcomes. In contrast to studies based solely on register 
data, the MAESTRO cohort includes biological data, data from questionnaires, data on lung 
function measurements as well as information from patient charts and national registers. 
All women that were admitted to the antenatal clinic in the first trimester of pregnancy were 
asked to participate, regardless of asthma or stress status. After consenting to the study, the 
midwife took a blood sample for IgE and DNA analyses. The participating woman then 
answered an online questionnaire on background factors, asthma status, stress etc. The 
participant also took two saliva samples (morning and evening sample) and sent them to a 
biobank. The same questionnaires and saliva samples were also taken in weeks 28-32 of 
pregnancy and 6 months after delivery. Around 250 women, half of which stated asthma or 
asthma-like symptoms in the first questionnaire and the other half healthy controls, were 
additionally asked to participate in spirometry tests. These included a reversibility test and 
provided data on FeNO and FEV1, in weeks 28-32 and 6 months after delivery. The lung 
function measurements were conducted at Karolinska Institutet, the Department of Medical 
Epidemiology and Biostatistics. Data regarding pregnancy and birth outcomes, as well as 
ultrasound records, with data on gestational age and foetal growth was collected from the 
antenatal clinic and delivery ward medical records. Additional data on diagnoses and 
dispensed medication were collected from the National Patient Register and the Swedish 
Prescribed Drugs Register. A flow chart of the study design is shown in Figure 3. 
 
 
Figure 3. Timeline of the MAESTRO study. Questionnaire and saliva sampling conducted at 
home. Blood sampling and lung function testing conducted at clinic. All available medical 
records and ultrasound data were collected after birth. 
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4.2 EXPOSURES 
4.2.1 Register Data 
Study I and II had maternal asthma as the exposure, in Study I asthma severity and asthma 
control were also assessed. 
An asthma ever diagnosis was identified if data on asthma disease was present in any of three 
different registers. Firstly, the Medical Birth Register as a tick box for asthma/lung disease 
ever- a question put by the treating midwife at the first antenatal visit in the first trimester of 
the pregnancy. Secondly, we identified physician diagnosis of asthma the National Patient 
Register, by the means of code 493 according to International Classification of Diseases, 
Ninth Revision (ICD-9), and codes J45 and J46 according to the International Classification 
of Diseases, Tenth Revision (ICD-10). For Study I, the diagnosis was identified in the year 
before pregnancy or during pregnancy (a current asthma diagnosis) and in Study II we used 
asthma diagnosis ever from the age 15 until delivery. Thirdly, in the Swedish Prescribed 
Drug Register we defined asthma as women with asthma medication (Anatomical 
Therapeutic Chemical Classification, ATC, codes R03AC, R03AK, R03BA, R03DC, H02) 
dispensed at least twice in the year before pregnancy and until delivery. The use of register-
based data when assessing asthma disease has been previously validated.111 Figure 4 shows 
the overlap in asthma disease between the different registers used. The majority of 
information came from the Medical Birth Register, and The National Patient Register mostly 
overlaps with the other registers but was still important in identifying 1% of the asthma cases. 
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Figure 4. The overlap of asthma ever in the different registers used for Study I. 
*The Medical Birth Register, §The Prescribed Drugs Register, † The National Patient 
Register. 
 
Asthma severity and asthma control was assessed in Study I using a previously validated 
index based on Canadian data by Firoozi et al.112 By looking at average prescribed doses of 
asthma medication as well as diagnosis for hospitalisation or emergency visits for asthma it is 
possible to determine both severity and control. The index was slightly modified by changing 
the number of filled prescriptions for long-acting β2 agonists, theophylline, and leukotriene 
receptor antagonists from six to two over a period of 12 months in order to adhere to Swedish 
prescription patterns, Table 1. 
  
†
† only
173 (1%)
† only
134 (1%)
† and PDR§ only
286 (1%)
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Table 1. Asthma severity modified from Firoozi et al.112 
 
 
For Study IV, our main exposure was current anxiety or depression and defined as at least 
two prescriptions of medication for anxiety or depression in the Swedish Prescribed Drugs 
Register (ATC-codes N05B and N06A) from the year before pregnancy until delivery and/or 
having an ICD-10 code for anxiety or depression (F30-34, F38-42, F44-45, F48) in the 
National Patient Register during the same period. Possible interaction between maternal 
asthma and anxiety or depression was evaluated in Study IV as well and we identified women 
with current asthma using data from the National Patient Register (ICD-10 codes J45 and 
J46) and the Prescribed Drugs Register (ATC-codes R03AC, R03AK, R03BA, and R03DC) 
as in Study I above. 
Asthma 
severity 
and control 
 
Inhaled 
corticosteroids 
(ICS), daily dose, 
µg (daily dose of 
ICS in 
beclomethasone-
chlorofluorocarbin 
equivalent over a 
12-month period) 
Other controller 
therapy (at least 
two prescriptions 
or long-acting β2 
agonists 
(LABA), 
theophylline or 
leukotriene 
receptor 
antagonists 
(LTRA) 
dispensed over a 
12-month period) 
Short acting 
β2 agonists 
(SABA) 
doses per 
week 
(average 
doses inhaled 
SABA per 
week 
calculated 
over a 12-
month period) 
Marker of 
moderate to severe 
exacerbations (an 
emergency 
department visit for 
asthma, a hospital 
admission for asthma 
or a filled 
prescription of an 
oral corticosteroid 
over a 12-month 
period) 
Mild 
asthma 
     
 Controlled 0-500 No 0-3 No 
  0-250 Yes 0-3 No 
 Uncontrolled 0-250 Yes 0-3 Yes 
  0-500 No 0-3 Yes 
  0-250 Yes 4-10 No 
  0-500 No 4-10 No 
Moderate 
asthma 
     
 Controlled 251-500 Yes 0-10 No 
  501-1000 Yes/No 0-10 No 
  >1000 Yes/No 0-3 No 
 Uncontrolled 0-250 Yes 4-10 Yes 
  0-500 No 4-10 Yes 
  0-250 Yes >10 No 
  0-500 No >10 No 
  251-500 Yes >10 No 
  251-500 Yes 0-10 Yes 
  501-1000 Yes/No >10 No 
  501-1000 Yes/No 0-10 Yes 
Severe 
asthma 
     
 Controlled >1000 Yes/No 4-10 No 
 Uncontrolled 0-1000 Yes/No >10 Yes 
  >1000 Yes/No 0-10 Yes 
  >1000 Yes/No >10 Yes/No 
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4.2.2 Clinical Data 
The exposures used in Study III of the thesis (the study based on the MAESTRO cohort) 
were maternal asthma ever as assessed from the medical charts (as a tick box for asthma/lung 
disease from the first antenatal visit), or from the first trimester questionnaires (self-reported 
physician diagnosed). The questionnaire also included data on asthma control from the 
Asthma Control Test (ACT), where a score ≤ 19 indicates uncontrolled and a score ≥ 20 
indicates controlled disease.9 
4.3 OUTCOMES 
4.3.1 Register Data 
Our studied outcomes in Study I were all collected from the Medical Birth Register and based 
on pregnancy- and delivery ICD-10-codes for preeclampsia/eclampsia (O14-15), gestational 
diabetes (O24), haemorrhage during pregnancy (O46), premature contractions (O47), 
premature rupture of membranes (O42), placental abruption (O45), dystocia during labour, 
induced/spontaneous onset of labour, caesarean section, CS, (which included elective or 
emergency CS prior to or emergency CS after onset of labour) and vaginal instrumental 
delivery (O62, O66.5, O81, O82). Based on the delivery codes, delivery mode was 
categorised as 1) vaginal, non-instrumental delivery, 2) elective CS (before start of labour), 3) 
vaginal instrumental delivery, and 4) emergency CS prior to or after start of labour. Birth 
outcomes and post-partum characteristics were also collected from the Medical Birth 
Register. Birth weight, gestational age, information on small and large for gestational age 
(defined as birth >2 standard deviations below or above reference curve for children of 
similar gestational age)113 were collected alongside data on Apgar score at 5 minutes,114 
haemorrhage after delivery (O72) and asphyxia/hypoxia in the child (P20-P21). 
For Study II and IV we identified the outcomes in the same way as in Study I but looked at 
fewer outcomes; preeclampsia/eclampsia, placental abruption, delivery mode, birth weight, 
gestational age as well as small and large for gestational age. 
4.3.2 Clinical Data 
In Study III we collected all data on the outcomes from the medical records. Our outcomes 
were early and late foetal growth as measured by ultrasound around week 20115 and birth 
weight. Early foetal growth was defined as growth discrepancy between first and second 
trimester estimates of gestational age, Figure 5. 
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Figure 5. Illustration of estimation of first and second trimester gestational age, and 
discrepancy between estimated and expected gestational age around gestational week 20. 
 
 
In the first trimester, we calculated the gestational age from 1) embryo transfer date, 2) first 
trimester ultrasound closest to week 10, 3) last menstrual period as reported at first antenatal 
visit, if an ultrasound was not available.  
The comparison between estimated and expected gestational age at the second trimester 
ultrasound resulted in a negative discrepancy (the foetus was smaller than expected), positive 
(the foetus was larger than expected) discrepancy, or no discrepancy (no deviation from 
expected pregnancy length). 
Positive and negative discrepancy was defined as deviation in number of days below 10th 
percentile or above 90th percentile from expected measurement. The reference category 
chosen was all measurements – discrepancies or not – between the 10th and 90th percentiles. 
We collected data on gestational age at birth, birth weight and birth length from the obstetric 
medical records. 
4.4 COVARIATES 
4.4.1 Register Data 
Possible confounders were chosen for studies I, II and IV based on previous knowledge about 
their effects on both exposures and outcomes and by the means of directed acyclic graphs 
(DAG:s).116 DAG:s are powerful when trying to identify covariates necessary to obtain 
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unconfounded estimates and are very helpful in determining pathways that are otherwise 
difficult to imagine, Figure 6. 
 
 
Figure 6. A DAG showing associations between exposure (yellow circle) and outcome (blue 
circle) with possible confounding factor, affecting both exposure and outcome (pink circle). 
Green line showing causal pathway. Often a mediator is present in the causal pathway 
(green circle). A collider (grey circle) is a factor that is caused by both exposure and 
outcome. Adjusting for a collider opens that path, causing a spurious association. 
 
 
The covariates chosen were collected from the Medical Birth Register and the longitudinal 
integration database for health and labour market studies (LISA) maintained by Statistics 
Sweden. The covariates used in the studies were: self-reported smoking at first antenatal visit 
(none, 1-9 cigarettes per day, > 9 cigarettes per day); body mass index (BMI in kg/m2) at first 
antenatal visit and calculated by height and weight; maternal age; parity; cohabitation; 
country of birth (Sweden/other Scandinavian countries/rest of the world); and socioeconomic 
status defined as the highest attained level of education. Data on maternal age and parity were 
recorded at delivery. 
4.4.2 Clinical Data 
We adjusted for possible confounders known to be associated with both the exposure and the 
outcomes, as in the register-based studies. They were maternal BMI, maternal smoking at 
first antenatal visit, level of education and data on cohabitation. As for exposure and 
outcomes, all data on covariates in Study III was collected from the medical records and the 
questionnaires. 
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4.5 STATISTICS 
Linear and logistic regression 
In a first step we studied the prevalence of asthma (Study I, II, III, and IV) and anxiety or 
depression (only Study IV) and the association with chosen covariates and outcomes. We 
then performed logistic and linear regression analyses for categorical and continuous 
variables. We estimated crude and adjusted odds ratios (OR) and beta coefficients with 95% 
confidence intervals for the full cohort. To account for the clustering of observations within 
women with multiple deliveries a sandwich estimator for the standard errors was used. 
In Study I, additional logistic regression analyses of asthma severity (with moderate/severe 
asthma compared to mild asthma as reference) and asthma control (uncontrolled asthma 
versus controlled) were done. The Holm-Bonferroni method117 was also applied to evaluate 
what significant results from the primary analyses would remain when applying an overall 
5% significance level for those tests.  
Family design 
In Study II and IV we also used conditional logistic regression, conditioning on full sibling 
pairs (same mother and father) and cousin pairs (common grandparents) in separate analyses, 
and for the continuous outcomes a linear regression model with fixed effects estimator. By 
doing so we could estimate associations between exposures and outcomes adjusted for 
genetic factors (full sisters share on average 50% and first cousins share on average 12.5% of 
segregated genes) and shared (familial) environment. The use of conditional regression, a 
within-family design, allows us to determine if the statistical association seen is due to 
familial confounding – if the comparison of discordant cousins or siblings will result in 
changed estimates, with a possible gradient from the full cohort, to cousins, to siblings, a 
possible familial confounding is present.100 As in the full cohort analyses, some women 
contributed with more than one pregnancy. Since there was dependency within clusters, we 
used bootstrapping to estimate correct 95% confidence intervals for the cousin and sibling 
analyses. 
Testing for Effect Modification and Interaction 
In Study I, we tested for effect modification of asthma control on disease severity by 
including interaction terms in the models. For Study IV, we also looked at the possible 
interaction between maternal asthma and maternal anxiety or depression by including an 
interaction term. In the linear regression models (with the continuous outcomes) this 
corresponds to interaction on the additive scale and in the logistic regression models 
(dichotomous outcomes) on the multiplicative scale. The differences in effects between the 
different models in both Study I and Study IV were tested with the likelihood ratio test. 
When evaluating possible interaction between two exposures it is not sufficient to only look 
at interaction on the multiplicative scale, which is common if testing for interaction in logistic 
regression models. Although multiplicative interaction may be important when trying to 
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assess causal mechanisms, looking at interaction on the additive scale can help determining 
importance on a public health scale. We estimated additive interaction for the dichotomous 
outcomes by calculating Relative Excess Risk due to Interaction (RERI).118 
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5 RESULTS AND DISCUSSION 
5.1 STUDY I AND II 
The asthma prevalence in Study I and II in pregnant women was around 10%. In Study I (n = 
284,214) we found that when the mothers had asthma there were increased risks for; 
preeclampsia/eclampsia, haemorrhage during pregnancy, premature contractions, premature 
rupture of membranes, placental abruption, labour dystocia, caesarean section, instrumental 
delivery, low birth weight, low gestational age, and small for gestational age, Figure 7a-b. 
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Figure 7a-b. Adjusted* odds ratios and 95% confidence intervals for the association between 
maternal asthma† and perinatal outcomes in Study I. 
*Adjusted for age, BMI, parity, smoking at antenatal care admission, country of birth, 
cohabitation/marital status, and level of education. 
†Asthma recorded in the Swedish Medical Birth Register, asthma diagnosis in the Swedish 
National Patient Register and/or asthma medication dispensed at least twice according to the 
Swedish Prescribed Drug Register. 
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In Study II (n = 1,075,153), we confirmed these associations for the outcomes we studied 
(preeclampsia – adjusted OR 1.17; 95% CI 1.13-1.21, placental abruption – adjusted OR 
1.27; 95% CI 1.15-1.41, instrumental delivery, caesarean section, lower birth weight, lower 
gestational age and small for gestational age – adjusted OR 1.18; 95% CI 1.12-1.23). In 
Study II, when adjusting for unmeasured genetic and environmental factors by comparing 
cousins and siblings discordant for exposure and outcomes, we saw that significant 
associations remained for preeclampsia, caesarean section, instrumental delivery, lower 
gestational age, and lower birth weight, Figure 8a-c. 
 
 
 
  25 
 
Figure 8a-c. Adjusted* odds ratios with 95% confidence intervals for the associations 
between maternal asthma† and adverse pregnancy, labour and perinatal outcomes. 
*Adjusted for age, BMI, parity, smoking at antenatal care admission, country of birth, 
cohabitation/marital status, and level of education  
†Asthma recorded in the Swedish Medical Birth Register, asthma diagnosis in the Swedish 
National Patient Register, and/or asthma medication dispensed at least twice from the year 
before pregnancy until delivery according to the Swedish Prescribed Drug Register. 
 
 
Moreover, in Study I, we saw that the risks of adverse outcomes such as low birth weight 
increased with increasing asthma severity, Figure 9a-c. 
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Figure 9a-c. Adjusted* odds rations with 95 % confidence intervals for the associations 
between moderate/severe asthma in the year before pregnancy and perinatal outcomes, mild 
asthma as reference. 
*Adjusted for age, BMI, parity, smoking at antenatal care admission, country of birth, 
cohabitation/marital status, and level of education. 
 
 
For women with uncontrolled compared to controlled asthma the results for adverse 
outcomes were inconsistent displaying both increased and decreased odds ratios for different 
outcomes, Figure 10a-c. 
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Figure 10a-c. Adjusted* odds ratios with 95% confidence intervals for the associations 
between perinatal outcomes and asthma control in the year before pregnancy. 
*Adjusted for asthma severity, country of birth, smoking at antenatal admission, cohabitation 
and marital status, maternal education level, BMI, maternal age at delivery. 
 
 
5.2 STUDY III 
In the MAESTRO-cohort (n = 1693), the asthma prevalence in pregnant women was 15%. 
Figure 11 shows the distribution of measured discrepancies between first and second 
trimester. We saw small mean discrepancies in days between estimated and expected 
gestational age at second trimester among women with (-1.2) and without (-1.1) asthma, and 
we did not see any significant differences between the groups (adjusted OR 1.57; 95% CI 
0.88-2.81 for a negative discrepancy of 6 days or more). Furthermore, we didn’t see any 
significant difference in mean gestational age, birth weight, or length of child. 
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Figure 11. Distribution of measured discrepancy in women with asthma and women without 
asthma. Discrepancy equals the difference in days between estimated and expected length of 
pregnancy at second trimester ultrasound scan, around gestational week 20. 
 
 
When assessing asthma control the mean discrepancy at the second trimester assessment was 
-2.0 days for women with uncontrolled asthma and -0.9 days for women with controlled 
asthma, however the differences between the groups again non-significant. 
5.3 STUDY IV 
In Study IV (n = 950,301), we found a prevalence of 5.9% for women in the cohort having 
anxiety or depression medication or diagnosis during the year before pregnancy until delivery 
(current disease). The prevalence of current maternal asthma was 4.0%, and only 0.5% were 
exposed to both anxiety or depression and asthma. Anxiety or depression was associated with 
higher odds for preeclampsia/eclampsia, caesarean section, vaginal instrumental delivery, 
lower mean birth weight, lower mean gestational age and large for gestational age. When 
comparing cousins and siblings discordant for the exposure and outcomes the point estimates 
changed very little or not at all, indicating no confounding from factors (genetic or 
environmental) shared within families, Appendix IV; Table 2 and Table 3. 
In the interaction analyses we could see that a combination of anxiety or depression and 
asthma showed higher odds ratios for most of the outcomes compared to the reference group 
having neither exposure, Appendix IV; Figure 1. Still we couldn’t see any additive interaction 
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between the two exposures. On the multiplicative scale, only elective caesarean section was 
affected by interaction between asthma and anxiety or depression. In a sensitivity analysis of 
women with a diagnosis for anxiety or depression with or without medication there were 
small differences between the groups, except for the outcome elective caesarean section 
where women without medication had significantly higher odds ratios for the outcome, 
Figure 12. 
 
 
Figure 12. Pregnancies with maternal anxiety/depression diagnose in the year before 
pregnancy until delivery with or without medication. Years 2006-2013. Adjusted* odds ratios 
with 95% confidence intervals for the associations between exposures and outcomes. 
*Adjusted for country of birth, smoking, cohabitation, maternal education level, BMI, age 
 
 
5.4 DISCUSSION AND METHODOLOGICAL CONSIDERATIONS 
We have been able to show that maternal asthma is associated with several serious 
pregnancy-, delivery and perinatal outcomes such as preeclampsia emergency caesarean 
section and small for gestational age. We have also demonstrated that the associations are not 
confounded by factors shared within families, such as common genes and environment. 
Indeed, it seems that asthma itself is responsible. We didn’t see any difference in early foetal 
growth in asthmatic mothers compared to pregnant women without asthma. We have also 
shown that maternal anxiety or depression during pregnancy is associated with many of the 
same outcomes as asthma, but there are no apparent interactions between the conditions. 
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5.4.1 Study designs 
Study I, II, and IV are all register-based and include data that have been prospectively 
collected, without any notion of our research questions. This approach has many advantages 
since it eliminates the risk of many types of bias that can be introduced for instance when 
setting up a clinical cohort such as selection bias. However, observational studies are prone to 
confounding and despite the fact that we considered and included possible confounders there 
are possible factors that are unmeasured that still could affect the estimates. By using 
relatives that to some extent share genes and environment (for instance siblings and cousins), 
but are discordant in terms of exposure and outcome, it is possible to account for some of 
these unmeasured confounding factors. We have been able to do this for Study II and IV and 
overall the estimates were found to be unchanged, suggesting that both asthma and anxiety or 
depression are causal in the effect on pregnancy and pregnancy outcomes. There are, 
however some limitations to this method. By choosing close relatives like siblings that differ 
in both exposure and outcome, they may be less alike than they would normally be by 
chance. This means that they will be more biased on non-shared factors than an unpaired 
estimate. Random measurement errors will also be attenuated in a within-pair-analysis, and 
since it is difficult to find discordant siblings or cousins, the power will be greatly reduced.99, 
119 We have tried to get data on exposure from different sources, such as the medical birth 
register, the national patient register and the prescribed drugs register in order to minimise the 
impact of measurement error and to increase power. 
In Study III we have collected data prospectively in a clinical cohort. Some of the data come 
from questionnaires in which we asked the participants about background factors and medical 
conditions. This approach can introduce recall bias and there is also a risk of selection bias in 
a clinical cohort since participants volunteer to be included and there is no random selection. 
Participants who are more educated or who have an interest in the disease may be more likely 
to enrol, and therefore included individuals may differ from the general population in terms 
of background factors such as education, and health. This is very hard to avoid, and adjusting 
for selection bias is difficult.120 Ways to minimise the introduction of selection bias, 
attempted in the MAESTRO study, is to recruit at different locations in order to get a more 
diverse study population, and to make the rationale of a study broader than just looking at one 
disease therefore appealing to a wider audience. 
5.4.2 Internal and external validity 
The selection of biased populations is harmful to the internal validity of the studies. 
Information bias or misclassification can also affect the internal validity and in the studies. 
For the register-based studies, any misclassification is more likely to be non-differential 
which means that the magnitude of the associations might be underestimated. The maternal 
diagnoses in the Medical Birth Register for instance are reliable to large extent. On the other 
hand, the infant diagnoses, other than, sex, gestational age, and birth weight suffer from low 
report rates, with missing data on up to 23%.104 Self-reported asthma and asthma control in 
Study III may be subject to report bias, with participants answering differently when they 
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know of the research question. Potential misclassification of exposure and/or outcomes (for 
instance measurement error by ultrasound scan) is most likely independent of each other, 
suggesting non-differential misclassification.121 
The external validity and generalisability of a study is dependent on the internal validity – 
without a good internal validity it’s difficult to generalise to other populations.122 For Study I, 
II, and IV we have identified all Swedish women that gave birth during the respective study 
period. This means that the results should be generalisable to other similar populations with 
similar characteristics, such as other westernised countries. Study III is smaller and based on 
pregnant women from a specific region (Stockholm) that attended eight different antenatal 
clinics. There may be limited generalisability to other populations, although we have 
strengthened the internal validity by adjusting for known possible confounders. 
5.4.3 Interaction analyses 
If the effects on the outcome by two exposures put together is different from the combination 
of the two effects considered separately an interaction is likely to be present. When looking at 
associations between exposures and outcomes it’s important to test for possible interactions, 
especially from a public health perspective, since it will help determining if two exposures of 
interest can be studied separately or should be considered together.123 Interaction can, as 
mentioned above, be tested on both additive and multiplicative scale. Even though 
multiplicative interaction can aid in determining underlying mechanisms, the magnitude is 
assessed by looking at additive interaction.124 In linear regression, additive interaction is 
easily calculated. For logistic regression models it is necessary to do additional calculations to 
determine the magnitude of additive interaction, for instance by the use of RERI (Relative 
Excess Risk due to Interaction).125 One might have assumed that there would be interaction 
between maternal asthma and anxiety/depression. However, we were unable to confirm this 
in Study IV, which means that the two exposures indeed can and should be assessed 
separately. 
5.4.4 Assessing early growth retardation 
In Study III we assessed maternal asthma as a risk factor for early growth retardation. The 
rationale for choosing this outcome was that we had seen in Study I and II and in other 
studies40, 126 that maternal asthma is a risk factor for the child being born small for gestational 
age, and low birth weight. We wanted to know if the growth retardation occurred early or late 
during pregnancy and by looking at the calculated gestational age at the second trimester 
routine ultrasound we would be able to determine when the growth retardation occurs. This 
way of assessing foetal growth comes with some assumptions. First, since we chose an early 
ultrasound as our reference point we assumed that early growth retardation occurs after the 
first trimester. There may also be growth restriction in the first trimester, but such an early 
reduction in foetal growth is associated with increased risk of subsequent miscarriage,127-129 
and never reaching 20 weeks of gestation. Second, we also assumed that all pregnancies have 
similar early growth, regardless of maternal or paternal influences. Indeed, previous studies 
 34 
show that this is mostly true, with standardised growth curves showing larger variance later in 
pregnancy.92, 96, 130 We therefore believe that, although resting on some assumptions, our 
method on assessing early foetal growth is valid. 
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6 ETHICAL CONSIDERATIONS 
Ethical consent for the studies has been obtained by the Regional Ethical Review Board in 
Stockholm; for Study I: 2010/1258-32. For Study II, III and IV: 2011/526-31/2 with 
amendments 2012/2199-32, 2014/971-32, 2014/2037-32. For Study III also with amendment 
2017/1679-32 and for Study IV also with amendment 2013/862-31/5. 
This PhD-project includes data collected both from register-based data linkage (Study I, II 
and IV) and from a clinical cohort (Study III). These have similar and some different ethical 
considerations. 
6.1 RISKS 
In register-based studies, although data have been de-identified, the gathered information is 
still very sensitive and needs to be held in a secure environment with secure servers, strong 
firewalls and encrypted, password-protected computers. To limit access to the personal data, 
only database administrators have access to all information stored and any researcher 
accesses only the re-anonymised linked variables they need. The published data must be 
presented on a group level (minimum 10 in a group). This means that identification of a 
single individual should not be possible. 
Normally study participants need to be informed of a study, and consent from each individual 
has to be collected. In a register-based study in Sweden, informed consent is often waived by 
the ethical review board. Also, studying common exposures and outcomes, such as asthma 
and pregnancy outcomes minimizes the risk of subgrouping to a level that would allow the 
identification of individuals and intruding on the personal integrity. 
For a study like the clinical Study III the approach was to obtain informed consent from each 
participant after careful and detailed information was provided to the participant about the 
study setup, including collection, storage, and security of data. The participants were also 
informed that they could at any given time and without any special reason withdraw from the 
study and, if they wanted, have their gathered data disposed of. To minimize the risk of 
intruding personal integrity, personnel performing tasks like bio sampling or lung function 
measurements were unaware of, for example, how the study person answered in the 
questionnaires and other aspects of the study. At time of analysis, all information on study 
persons was de-identified. 
If interventions in a clinical study are part of routine health care, e.g. spirometry, no apparent 
associated risks are normally present. If interventions are not within the scope of routine 
health care, further considerations regarding risks and benefits must be taken. 
6.2 BENEFITS 
For register-based studies, there are no immediate individual benefits for a study participant. 
In a clinical study (like our Study III) there are possible benefits on an individual level since, 
for example, a participant can get access to important health parameters concerning her health 
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status and thereby can get information on whether she needs to for instance alter her 
medication. 
For all studies there are possible benefits on a population level, meaning that the results can 
help the understanding and course of a disease and maybe how to better control it. In that 
sense there are many more individuals with a potential benefit than only those participating in 
a study. 
6.3 ETHICAL CONCLUSION 
In conclusion, there are some risks with all studies. But with a good research question and 
having strict rules set up for collecting samples, analysing and storing of data and 
presentation of results, the potential benefits to the society that this particular research adds 
overweigh the risks. 
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7 INTERPRETATION AND CONCLUSION 
Maternal asthma is associated with a number of serious pregnancy complications and adverse 
perinatal outcomes (Study I and II). Some complications are more frequent with increased 
asthma severity (Study I). Maternal asthma seems not to be associated with early foetal 
growth restriction (Study III). Maternal anxiety or depression during pregnancy is also 
associated with adverse outcomes in pregnancy, and although showing similarities with 
maternal asthma during pregnancy, we could not detect significant interactions between the 
conditions (Study IV). 
After adjusting for familial confounding conditioning on siblings and cousins, asthma as well 
as anxiety or depression remains significantly associated with adverse pregnancy outcomes 
(Study II and IV).  
Targeting the asthma disease and anxiety or depression in the pregnant mother will continue 
to be important in reducing risks for adverse outcomes in pregnancy. With greater awareness 
and proper management, outcomes would most likely improve. 
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8 FUTURE PERSPECTIVES 
Asthma burdens pregnancies, affecting both mother and offspring, as we have seen in the 
studies covered in this thesis. Ideally, we would be able to prevent adverse events by 
identifying early those women affected and managing their disease in an optimal way. This 
could be achieved by setting up specific antenatal clinics for women with asthma, similar to 
those for women with diabetes during pregnancy.131, 132 
We have seen that although there are some differences in how asthma severity and control 
affect our studied outcomes, asthma poses risks regardless of the level severity or control. 
One of the major difficulties is to determine which women would benefit the most from more 
intense interventions. Perhaps asthmatic women with an allergic phenotype are the ones with 
the highest risk of adverse events, as this is considered one of the driving pathways towards 
more severe disease.8, 133 
Future research on maternal asthma should look more into the possibilities of determining 
asthma phenotypes – by assessing genetic traits, allergies, and lung function measurements – 
and how they affect pregnancy outcomes, with much of this data is already collected within 
the scope of the MAESTRO study. In order to determine when foetal growth retardation in 
asthmatic women occurs during pregnancy, larger studies with more ultrasound measurement 
data are needed. Large cohorts looking at seasonal differences could also help assess if foetal 
growth retardation in asthmatic women is more likely if pollen season occurs during the first, 
second or third trimester of pregnancy. 
Intervention studies on maternal asthma, perhaps in a specialised antenatal clinic setting, 
could help improve outcomes in women affected. Intervention should focus treating those 
with the worst expected outcomes. One way of doing this is by monitoring the fraction of 
exhaled nitric oxide (FeNO) levels for early intervention to limit the inflammatory process, 
something that has been studied previously134, 135 but outcomes can be expanded to include 
more maternal complications such as preeclampsia. 
Women with internalising disorders such as stress, anxiety or depression have not only higher 
risks for post-partum depression but also for adverse outcomes in pregnancy as we have been 
able to show in Study IV. Among other things we could see that women with diagnosis of 
anxiety or depression had higher odds for elective caesarean section if they were not on 
medication. While several of the outcomes studied may be difficult to prevent, elective 
caesarean section is associated with severe morbidity and often preventable.136, 137 Greater 
awareness of our found associations in maternal and obstetric health care is necessary. Based 
on Study IV data it’s difficult to determine why some of the women with anxiety or 
depression diagnosis were not using medication. Future studies on stress, anxiety or 
depression during pregnancy should focus on optimising treatment and reducing rates of 
caesarean section by an early intervention. Closer monitoring of women with anxiety or 
depression in specialised antenatal clinics (clinics that are many times implemented already) 
is vital for such an early intervention.  
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9 SVENSK SAMMANFATTNING 
Astma liksom ångest och depression är associerade med komplikationer under graviditet och 
förlossning. Det finns också samband mellan ångest/depression och astma och det kan finnas 
gemensamma mekanismer bakom hur dessa åkommor påverkar graviditet och 
graviditetsutfall. Till exempel skulle en del av associationerna kunna förklaras av genetiska 
faktorer eller miljöfaktorer, faktorer som delas inom familjer. I denna avhandling har vi 
studerat hur astma och ångest eller depression påverkar graviditet och förlossning i en 
kombination av stora populationsbaserade studier och en mindre klinisk kohort. Med hjälp av 
familjedesign som statistisk metod har vi tagit hänsyn till genetiska faktorer och delad miljö. 
I Studie I och II har vi i nationella studiepopulationer tittat på sambandet mellan moderns 
astma och graviditets- och förlossningsutfall såsom havandeskapsförgiftning, 
moderkaksavlossning, förlossningssätt, födelsevikt och graviditetslängd vid födseln. I Studie 
II identifierade vi kusiner och systrar som var gravida och födde barn under samma 
studieperiod. Vi fann samband mellan moderns astma och många av de studerade utfallen, 
tex havandeskapsförgiftning (Studie I och II) och sambanden kunde inte förklaras av andra 
faktorer (genetik eller miljö) inom familjer (Studie II). Vi såg också ökad risk för vissa av 
utfallen vid svårare eller sämre kontrollerad astma (Studie I). 
I Studie III undersökte vi hur moderns astma påverkade tidig fetal tillväxt genom att använda 
oss av data från rutinultraljudet i andra trimestern. Studiepopulationen vi använde oss av var 
MAESTRO-studien där 1693 kvinnor följdes under graviditeten. Vi kunde inte se någon 
signifikant skillnad mellan kvinnor med och utan astma och tidig fetal tillväxt. Vi kunde inte 
heller se någon skillnad mellan grupperna när vi tittade på födelsevikt och graviditetslängd 
vid födseln. 
I Studie IV undersökte vi, med hjälp av en nationell studiepopulation, sambandet mellan 
ångest eller depression hos den gravida kvinnan och avvikande graviditets- och 
förlossningsutfall. Vi fann samband mellan ångest eller depression hos modern och flera 
avvikande utfall och att sambanden inte kunde förklaras av faktorer som delades inom 
familjer (mellan kusiner eller systrar). Vi såg inte heller någon interaktion mellan ångest eller 
depression och astma för något utfall, förutom vid planerat kejsarsnitt. Vi såg också högre 
oddskvoter för planerat kejsarsnitt hos kvinnor med ångest eller depressionsdiagnos utan 
medicinering jämfört med kvinnor som medicinerade. 
Sammanfattningsvis har vi kunnat visa att astma liksom ångest eller depression är associerade 
med allvarliga graviditets- och förlossningskomplikationer. Genetiska faktorer eller 
miljöfaktorer som delas av familjer kan inte förklara sambanden. Förutom vid planerat 
kejsarsnitt kunde vi inte se någon interaktion mellan ångest eller depression och astma under 
graviditeten vid de studerade utfallen. Det betyder att både ångest eller depression och astma 
hos den gravida kvinnan fortsätter vara viktiga mål för att minska risken för graviditets- och 
förlossningskomplikationer. Större medvetenhet och optimal behandling förbättrar sannolikt 
utfallen för både kvinnan och barnet. 
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